New Results
Programmable in vivo CRISPR activation elucidates the oncogenic and immunosuppressive role of MYC in lung adenocarcinoma
View ORCID ProfileFredrik I. Thege, Dhwani N. Rupani, Bhargavi B. Barathi, Sara L. Manning, Anirban Maitra, Andrew D. Rhim, Sonja M. Wörmann
doi: https://doi.org/10.1101/2021.12.09.471859
Fredrik I. Thege
1Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Translational Molecular Pathology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Dhwani N. Rupani
3Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Bhargavi B. Barathi
4Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Sara L. Manning
1Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Anirban Maitra
1Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Translational Molecular Pathology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Andrew D. Rhim
1Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Sonja M. Wörmann
1Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Department of Translational Molecular Pathology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Article usage
Posted December 09, 2021.
Programmable in vivo CRISPR activation elucidates the oncogenic and immunosuppressive role of MYC in lung adenocarcinoma
Fredrik I. Thege, Dhwani N. Rupani, Bhargavi B. Barathi, Sara L. Manning, Anirban Maitra, Andrew D. Rhim, Sonja M. Wörmann
bioRxiv 2021.12.09.471859; doi: https://doi.org/10.1101/2021.12.09.471859
Programmable in vivo CRISPR activation elucidates the oncogenic and immunosuppressive role of MYC in lung adenocarcinoma
Fredrik I. Thege, Dhwani N. Rupani, Bhargavi B. Barathi, Sara L. Manning, Anirban Maitra, Andrew D. Rhim, Sonja M. Wörmann
bioRxiv 2021.12.09.471859; doi: https://doi.org/10.1101/2021.12.09.471859
Subject Area
Subject Areas
- Biochemistry (11574)
- Bioengineering (8626)
- Bioinformatics (28876)
- Biophysics (14809)
- Cancer Biology (11945)
- Cell Biology (17175)
- Clinical Trials (138)
- Developmental Biology (9309)
- Ecology (14023)
- Epidemiology (2067)
- Evolutionary Biology (18130)
- Genetics (12148)
- Genomics (16621)
- Immunology (11712)
- Microbiology (27705)
- Molecular Biology (11402)
- Neuroscience (60109)
- Paleontology (448)
- Pathology (1849)
- Pharmacology and Toxicology (3185)
- Physiology (4878)
- Plant Biology (10279)
- Synthetic Biology (2850)
- Systems Biology (7291)
- Zoology (1619)